Raymond James Sees ‘Knee-Jerk’ AI Reaction, Reaffirms Strong Buy on Doximity, Inc. (DOCS)

Core Viewpoint - Doximity, Inc. (NYSE:DOCS) is recognized as a promising growth stock, with analysts highlighting its potential amidst increasing competition in healthcare AI tools, particularly following OpenAI's recent entry into the sector [1]. Group 1: Analyst Ratings and Price Targets - Raymond James reaffirmed a 'Strong Buy' rating on Doximity, Inc. with a price target of $65, indicating confidence in the company's growth potential [1]. - The firm maintained a 'Strong Buy' rating on December 29, 2025, after a meeting with Co-founder and CEO Jeff Tangney, suggesting ongoing positive sentiment towards the company [2]. Group 2: Company Performance and Market Position - Analysts believe that Doximity's engagement is set to accelerate, providing a "durable" revenue growth driver over time, which may not be fully recognized by investors [3]. - Doximity's EBITDA margins are expected to expand further from the current 55%, indicating strong financial health and operational efficiency [3]. - The company's "physicians-first ethos" is viewed as a structural moat that differentiates it from competitors, suggesting a competitive advantage in the market [3]. Group 3: Company Overview - Doximity, Inc. is a California-based digital platform for medical professionals, founded in 2010, serving a diverse customer base including physicians, medical students, pharmaceutical manufacturers, and healthcare systems [4].